Royal college

QS World University Rankings by Subject 2023

Retrieved on: 
Wednesday, March 22, 2023

LONDON, March 22, 2023 /PRNewswire/ -- Global higher education analyst QS Quacquarelli Symonds has released the thirteenth edition of the QS World University Rankings by Subject, revealing the top universities in 54 academic disciplines, including three brand-new additions: Data Science, Marketing, and History of Art.

Key Points: 
  • LONDON, March 22, 2023 /PRNewswire/ -- Global higher education analyst QS Quacquarelli Symonds has released the thirteenth edition of the QS World University Rankings by Subject , revealing the top universities in 54 academic disciplines, including three brand-new additions: Data Science, Marketing, and History of Art.
  • The rankings are based on an independent comparative analysis of over 15,700 individual university programs taken by students at 1,594 universities in 93 countries and territories.
  • The rankings were consulted over 120 million times in 2022 on TopUniversities.com and referenced 117,000 times by media globally.
  • Ben Sowter, QS Senior Vice President, said: "Our largest-ever subjects rankings provides a deeper understanding of how global higher education excellence is achieved.

Leading Diabetes Researcher Speaks on his Groundbreaking ‘Edmonton Protocol’ with CancerVAX CEO Ryan Davies

Retrieved on: 
Wednesday, March 22, 2023

LEHI, Utah, March 22, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that CEO Ryan Davies spoke with world-renown diabetes researcher Dr. Jonathan Lakey.

Key Points: 
  • LEHI, Utah, March 22, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that CEO Ryan Davies spoke with world-renown diabetes researcher Dr. Jonathan Lakey.
  • Specifically, Dr. Lakey’s Edmonton Protocol involves a procedure in which pancreatic beta-islet cells are transplanted in type I diabetes mellitus patients.
  • “Dr.
  • Lakey is an incredibly talented individual,” CancerVAX CEO Ryan Davies said, “His work on the Edmonton Protocol in addition to his hundreds of contributions to scientific research are incredibly important for helping type I diabetes patients.”
    For more information about CancerVax, please visit http://www.cancervax.com/ .

ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200

Retrieved on: 
Tuesday, March 7, 2023

“We are honored that Dr. Glassock, an internationally recognized authority in the field of glomerular disease, is joining our Scientific Advisory Board,” stated Dr. Pablo Guzman, ZyVersa’s Chief Medical Officer and Chairman of the Renal Scientific Advisory Board.

Key Points: 
  • “We are honored that Dr. Glassock, an internationally recognized authority in the field of glomerular disease, is joining our Scientific Advisory Board,” stated Dr. Pablo Guzman, ZyVersa’s Chief Medical Officer and Chairman of the Renal Scientific Advisory Board.
  • His main interests are in glomerular disease, chronic kidney disease, and clinical nephrology.
  • Dr. Glassock was the former Chair of the Departments of Medicine at the University of Kentucky (1992-1999) and Harbor-UCLA Medical Center (1980-1992).
  • He is a Master of The American College of Physicians and a Fellow of The Royal College of Physicians (UK).

Annunziato (Ned) Amendola, MD, FAAOS, FRCSC, DABOS, Named Second Vice President of the American Academy of Orthopaedic Surgeons

Retrieved on: 
Thursday, March 9, 2023

LAS VEGAS, March 9, 2023 /PRNewswire/ -- North Carolina orthopaedic surgeon Annunziato (Ned) Amendola, MD, FAAOS, FRCSC, DABOS, division chief for sports medicine at Duke University, was named second vice president of the American Academy of Orthopaedic Surgeons' (AAOS) Board of Directors.

Key Points: 
  • LAS VEGAS, March 9, 2023 /PRNewswire/ -- North Carolina orthopaedic surgeon Annunziato (Ned) Amendola, MD, FAAOS, FRCSC, DABOS, division chief for sports medicine at Duke University, was named second vice president of the American Academy of Orthopaedic Surgeons' (AAOS) Board of Directors.
  • Following the AAOS 2023 Annual Meeting in Las Vegas this week, he will assume the second vice president position.
  • He is the past president of the American Orthopaedic Society of Sports Medicine and the Herodicus Orthopaedic Society.
  • He was also deputy editor of the Journal of the American Academy of Orthopaedic Surgeons.

PrecisionOS Revolutionizes Orthopedic Residency Education with Immersive Virtual Reality Surgical Curriculum

Retrieved on: 
Tuesday, March 7, 2023

VANCOUVER, BC, March 7, 2023 /PRNewswire/ - PrecisionOS®, a leading medical education simulation provider announced today a novel virtual reality curriculum for orthopedic training.

Key Points: 
  • VANCOUVER, BC, March 7, 2023 /PRNewswire/ - PrecisionOS®, a leading medical education simulation provider announced today a novel virtual reality curriculum for orthopedic training.
  • The company has put together an extensive guide aimed at all residency programs in North America and beyond.
  • "This virtual reality curriculum represents a true game-changer in surgical education," said Dr. Peter Ferguson, Albert and Temmy Latner Chair of the Division of Orthopedics, Department of Surgery, University of Toronto.
  • This virtual reality curriculum is now available for all orthopedic surgical residency programs in North America and will be released at the American Academy of Orthopedic Surgeons Annual Meeting in Las Vegas March 7-11, 2023.

Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends

Retrieved on: 
Friday, March 3, 2023

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
Wednesday, February 15, 2023

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
Wednesday, February 15, 2023

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.

Key Points: 
  • SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.
  • https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-tria...
    The webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:
    - The COVID-19 impact on drug development and the regulatory landscape.
  • - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage.
  • - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.